Format

Send to

Choose Destination
Laryngoscope Investig Otolaryngol. 2019 Jan 10;4(1):62-69. doi: 10.1002/lio2.235. eCollection 2019 Feb.

The evolving role of immuno-oncology for the treatment of head and neck cancer.

Author information

1
School of Medicine University of Michigan Ann Arbor Michigan.
2
Department of Otorhinolaryngology-Head and Neck Surgery University of Maryland School of Medicine Baltimore Maryland.
3
College of Medicine University of Tennessee Health Science Center Memphis Tennessee.

Abstract

Monoclonal antibodies (mAbs) that target immune co-signaling pathways have the potential to enable immune mediated tumor eradication. While early adoption of these agents for the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN) has produced some astounding clinical successes, the majority of patients fail to respond to therapy. The purpose of this review is to first provide a broad overview of the immuno-oncology (I-O) landscape and to then focus on the current status of mAb-based I-O (mAb:I-O) for the treatment of SCCHN, with particular attention to the development of strategies for improving treatment responses.

KEYWORDS:

Immuno‐oncology; head and neck cancer

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center